Bulk CD34+ Cells from GCSF Mobilized Leukopaks CellsExpress
High yield CD34+ hematopoietic stem and progenitor cells isolated from GCSF mobilized leukopaks. Bulk processing up to 2 x 10e10 TNC with ≥80% post thaw viability and high purity for stem cell and gene therapy research.
Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies. By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.
Description
CD34+ hematopoietic stem and progenitor cells isolated from GCSF mobilized leukopaks are essential for stem cell therapy development, gene editing workflows, and translational research.
CellsExpress bulk CD34+ isolation from GCSF mobilized leukopaks is designed for programs that require high recovery, high purity stem cell populations without the risk and variability of in house processing.
Using large scale processing of mobilized collections, we process up to 2 x 10e10 total nucleated cells per leukopak to maximize CD34+ yield and deliver cryopreserved cells ready for immediate downstream use.
Mobilization with GCSF enriches circulating CD34+ stem and progenitor cells, enabling scalable workflows for advanced therapeutic development.
Key Features
• CD34+ cells isolated from GCSF mobilized leukopaks
• Up to 2 x 10e10 total nucleated cells processed
• ≥80% post thaw viability
• High purity CD34+ enrichment
• Cryopreserved and ready for immediate use
• Custom vial sizing available
• HLA typing and recallable donors available
Ideal Applications
• Hematopoietic stem cell therapy development
• Gene editing platforms including CRISPR workflows
• Stem cell expansion and differentiation studies
• Process development and assay optimization
• In vivo efficacy and safety studies
• Scalable CD34+ cell banking
Programs working with limited mobilized donors or high value collections cannot afford yield loss. CellsExpress bulk CD34+ isolation protects recovery while reducing internal laboratory burden and timeline risk.
Additional information
| Anticoagulant | |
|---|---|
| Format | |
| Grade | |
| Species | |
| Cell and Tissue Source | |
| Disease State | |
| Donor Attributes |
Product Information Sheet
Mobilized Peripheral Blood
Selected publications demonstrating the use of mobilized peripheral blood and mobilized leukopak-derived CD34+ hematopoietic stem and progenitor cells in gene therapy, cell therapy, and transplantation workflows.
Hematopoietic reconstitution dynamics of mobilized peripheral blood-derived stem cells after gene therapy
Nature Communications · 2023
Mobilized peripheral blood-derived hematopoietic stem and progenitor cells were used for gene therapy, showing improved engraftment and recovery compared to traditional sources.
Mobilized Blood · HSPC · Gene Therapy
In vivo CRISPR gene editing in hematopoietic stem cells
Nature Biotechnology · 2022
Mobilized CD34+ hematopoietic stem cells were used in gene editing workflows to evaluate therapeutic genome engineering strategies.
CD34+ Cells · CRISPR · Gene Editing
Ex vivo expansion and functional characterization of hematopoietic stem cells
Stem Cell Research · 2023
Mobilized peripheral blood-derived hematopoietic stem cells were expanded ex vivo and evaluated for functional and therapeutic potential.
HSPC · Expansion · Stem Cell Biology
Optimized lentiviral production and transduction of primary human cells
Molecular Therapy Methods & Clinical Development · 2024
Mobilized CD34+ cells and primary immune cells were transduced using optimized viral production systems for gene and cell therapy applications.
CD34+ Cells · Viral Transduction
Improved workflows for gene modification in hematopoietic stem cells
Molecular Therapy Methods & Clinical Development · 2024
Mobilized hematopoietic stem cells were used to evaluate improved gene modification and cell engineering workflows.
Gene Editing · HSPC
Mobilized peripheral blood stem cells in transplantation and hematologic recovery
Blood · 2023
Mobilized peripheral blood stem cells were used in transplantation workflows to evaluate hematologic recovery and clinical outcomes.
Transplantation · Mobilized Blood
Related products
-
Bone Marrow Mesenchymal Stem Cells, Fresh
Select options This product has multiple variants. The options may be chosen on the product page -
Peripheral Blood CD4+CD25+ Regulatory T Cells, Frozen
Select options This product has multiple variants. The options may be chosen on the product page -
Whole Blood, Fresh, EDTA
Select options This product has multiple variants. The options may be chosen on the product page -
Bone Marrow CD133+ Stem/Progenitor Cells, Frozen
Select options This product has multiple variants. The options may be chosen on the product page
